# Fulgent Genetics, Inc.: overview

FLGT · Nasdaq · CIK 1674930 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/flgt.md) · [Financials](/companies/flgt/financials.md) · [Filings](/companies/flgt/filings.md) · [Insiders](/companies/flgt/insiders.md)

Latest reported revenue: [$85.4m](/filings/0001193125-26-326136.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Jul 30, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-326136).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [71.7](/filings/0001193125-25-271013.md) | [76.2 d](/filings/0001193125-26-079169.md) | [73.5](/filings/0001193125-26-199065.md) | [81.8](/filings/0001193125-26-326136.md) | [84.1](/filings/0001193125-25-271013.md) | [83.3 d](/filings/0001193125-26-079169.md) | [71.1](/filings/0001193125-26-199065.md) | [85.4](/filings/0001193125-26-326136.md) |
| Gross margin | % | [37.3%](/filings/0001193125-25-271013.md) | [41.8% d](/filings/0001193125-26-079169.md) | [38.6%](/filings/0001193125-26-199065.md) | [42.1%](/filings/0001193125-26-326136.md) | [42.2%](/filings/0001193125-25-271013.md) | [39.1% d](/filings/0001193125-26-079169.md) | [30.2%](/filings/0001193125-26-199065.md) | [30.1%](/filings/0001193125-26-326136.md) |
| Operating margin | % | [(23.8%)](/filings/0001193125-25-271013.md) | [(21.2%) d](/filings/0001193125-26-079169.md) | [(26.9%)](/filings/0001193125-26-199065.md) | [(24.1%)](/filings/0001193125-26-326136.md) | [(18.3%)](/filings/0001193125-25-271013.md) | [(43.5%) d](/filings/0001193125-26-079169.md) | [(48.7%)](/filings/0001193125-26-199065.md) | [(42.2%)](/filings/0001193125-26-326136.md) |
| Net margin | % | [(20.4%)](/filings/0001193125-25-271013.md) | [(7.7%) d](/filings/0001193125-26-079169.md) | [(15.7%)](/filings/0001193125-26-199065.md) | [(23.2%)](/filings/0001193125-26-326136.md) | [(7.9%)](/filings/0001193125-25-271013.md) | [(28.1%) d](/filings/0001193125-26-079169.md) | [(34.9%)](/filings/0001193125-26-199065.md) | [(34.6%)](/filings/0001193125-26-326136.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Free cash flow | $m | [(35.0) d](/filings/0001193125-25-271013.md) | [21.2 d](/filings/0001193125-26-079169.md) | [(9.1)](/filings/0001193125-26-199065.md) | [(37.0) d](/filings/0001193125-26-326136.md) | [5.1 d](/filings/0001193125-25-271013.md) | [(83.1) d](/filings/0001193125-26-079169.md) | [1.9](/filings/0001193125-26-199065.md) | [(27.6) d](/filings/0001193125-26-326136.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL not reported.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [993](/filings/0000950170-24-022233.md) | [619](/filings/0000950170-25-029512.md) | [289](/filings/0001193125-26-079169.md) | [283](/filings/0001193125-26-079169.md) | [323](/filings/0001193125-26-079169.md) |
| Gross margin | % | [78.3%](/filings/0000950170-24-022233.md) | [59.3%](/filings/0000950170-25-029512.md) | [36.1%](/filings/0001193125-26-079169.md) | [37.8%](/filings/0001193125-26-079169.md) | [40.6%](/filings/0001193125-26-079169.md) |
| Operating margin | % | [68.1%](/filings/0000950170-24-022233.md) | [28.8%](/filings/0000950170-25-029512.md) | [(67.6%)](/filings/0001193125-26-079169.md) | [(26.1%)](/filings/0001193125-26-079169.md) | [(28.2%)](/filings/0001193125-26-079169.md) |
| Net margin | % | [51.1%](/filings/0000950170-24-022233.md) | [23.2%](/filings/0000950170-25-029512.md) | [(58.0%)](/filings/0001193125-26-079169.md) | [(15.1%)](/filings/0001193125-26-079169.md) | [(18.8%)](/filings/0001193125-26-079169.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported |
| Free cash flow | $m | [515](/filings/0000950170-24-022233.md) | [235](/filings/0000950170-25-029512.md) | [4.8](/filings/0001193125-26-079169.md) | [(19.3)](/filings/0001193125-26-079169.md) | [(124)](/filings/0001193125-26-079169.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL not reported.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/flgt/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $46.9m | 2,286,669 |  | Reduced −487,850 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $16.2m | 789,498 |  | Reduced −90,652 |
| [JACOBS LEVY EQUITY MANAGEMENT, INC](/funds/884414.md) | 2026-06-30 | $16.0m | 782,116 |  | Added +425,757 |
| [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $15.5m | 756,558 |  | Added +296,195 |
| [Diametric Capital, LP](/funds/1719087.md) | 2026-06-30 | $14.3m | 697,784 |  | Added +336,738 |
| [AMERIPRISE FINANCIAL INC](/funds/820027.md) | 2026-06-30 | $13.8m | 670,084 |  | Added +106,709 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $12.8m | 625,355 |  | Reduced −46,309 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $10.7m | 521,014 |  | Reduced −63,193 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $10.2m | 498,673 |  | Reduced −30,726 |
| [Invenomic Capital Management LP](/funds/1769456.md) | 2026-06-30 | $10.2m | 498,287 |  | Reduced −112,031 |

## Recent filings

[All 661 filings](/companies/flgt/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-07-30 | 16:13 ET | [10-Q](/filings/0001193125-26-326136.md) | Quarterly report, period 2026-06-30 | 0001193125-26-326136 |
| 2026-07-30 | 16:09 ET | [8-K](/filings/0001193125-26-326119.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-326119 |
| 2026-06-02 | 19:07 ET | [8-K](/filings/0001674930-26-000028.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001674930-26-000028 |
| 2026-05-27 | 19:42 ET | [SCHEDULE 13D/A](/filings/0001302110-26-000020.md) | Ownership report, active investor, amended | 0001302110-26-000020 |
| 2026-05-21 | 17:04 ET | [8-K](/filings/0001674930-26-000025.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001674930-26-000025 |
| 2026-05-14 | 16:27 ET | [8-K](/filings/0001193125-26-224147.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-224147 |
| 2026-05-01 | 07:08 ET | [10-Q](/filings/0001193125-26-199065.md) | Quarterly report, period 2026-03-31 | 0001193125-26-199065 |
| 2026-05-01 | 07:03 ET | [8-K](/filings/0001193125-26-199061.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-199061 |
| 2026-03-31 | 16:55 ET | [SCHEDULE 13D/A](/filings/0001302110-26-000013.md) | Ownership report, active investor, amended | 0001302110-26-000013 |
| 2026-03-31 | 16:11 ET | [DEF 14A](/filings/0001674930-26-000020.md) | Proxy statement, period 2026-03-31 | 0001674930-26-000020 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-079169.md), filed Feb 27, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/58e3c92b-4a40-4c36-807d-2055c2a489d4)

## About the filer

- CIK: 1674930
- Tickers: FLGT
- Exchange: Nasdaq
- SIC code: 8071 Services-Medical Laboratories
- State of incorporation: DE
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.